FDA expects organizations to document how the decision was reached, not simply state that an event was not reportable. The evaluation should explain what information was reviewed, how applicable reporting criteria were assessed, and why the conclusion was justified.

Inspection concerns often arise when similar events receive different reporting decisions or when conclusions rely on assumptions instead of documented analysis. Consistency is as important as the final decision itself.

Records showing who reviewed the event, what evidence was considered, and how uncertainties were addressed provide stronger regulatory support. A structured review process demonstrates that the decision was deliberate rather than subjective.

Well-supported documentation is often more defensible than the outcome alone. Clear reasoning allows inspectors to understand the organization's judgment and reduces questions about whether reportable events may have been overlooked.

Recall discussions should begin when available evidence indicates a potential risk to patients or users, even if the investigation is still underway. Waiting for complete technical certainty can delay necessary risk management actions.

Repeated complaints, serious injuries, or emerging failure trends often justify an early assessment of whether market action should be considered. Initial decisions should reflect the potential impact rather than the completeness of the investigation.

Inspectors frequently review whether organizations evaluated risk as new information became available. Delayed discussions about recall decisions can become difficult to defend when records show escalating evidence of product issues.

Documentation should explain the information available at each decision point, the interim controls implemented, and why the chosen approach remained appropriate. This demonstrates disciplined, risk-based decision making throughout the investigation.

Inspection findings commonly result from inconsistent complaint evaluations rather than the number of complaints received. Missing investigations, weak justifications, or incomplete documentation often raise questions about the effectiveness of the quality system.

Another recurring concern is the failure to connect complaint data with corrective actions, trend analysis, adverse event reporting, or manufacturing investigations. Isolated complaint records rarely demonstrate meaningful quality oversight.

Inspectors also look for recurring issues that were evaluated individually but never recognized as broader trends. Missing these patterns weakens confidence in management's ability to detect developing product risks.

Organizations with consistent evaluation criteria, complete documentation, and traceable follow-up actions are generally better able to demonstrate that complaint handling supports informed quality decisions instead of functioning only as an administrative process.

Consistency comes from applying the same documented evaluation process across the organization rather than expecting identical reporting outcomes. Different products may require different conclusions, but the decision framework should remain consistent.

Inspection concerns often arise when similar events receive different reporting decisions without documented justification. Regulators frequently compare records across products, sites, and reporting periods to identify unexplained differences.

Cross-site governance reviews, internal audits, and standardized decision criteria help demonstrate that reporting expectations are interpreted consistently. These activities also identify variations before they become regulatory concerns.

Strong documentation explains why decisions differ when product-specific factors are involved while showing that every event received the same level of regulatory review. That evidence is far more persuasive than relying on individual reviewer judgment alone.